180 related articles for article (PubMed ID: 10466436)
1. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Arah IN; Dixon SC; Horti J; Figg WD
Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Pienta KJ; Smith DC
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
[TBL] [Abstract][Full Text] [Related]
3. Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model.
Abramjuk C; Lein M; Rothaug W; Krell HW; Loening SA; Jung K
Cancer Chemother Pharmacol; 2007 Feb; 59(2):275-82. PubMed ID: 16758188
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance in prostate cancer cell lines is influenced by androgen dependence and p53 status.
Serafin AM; Akudugu JM; Bohm L
Urol Res; 2002 Oct; 30(5):289-94. PubMed ID: 12389116
[TBL] [Abstract][Full Text] [Related]
5. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
6. Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
Mackler NJ; Dunn RL; Hellerstedt B; Cooney KA; Fardig J; Olson K; Pienta KJ; Smith DC
Cancer; 2006 Jun; 106(12):2617-23. PubMed ID: 16691618
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Smith DC; Chay CH; Dunn RL; Fardig J; Esper P; Olson K; Pienta KJ
Cancer; 2003 Jul; 98(2):269-76. PubMed ID: 12872344
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer].
Awakura Y; Yamamoto M; Fukuzawa S; Itoh N; Nonomura M; Fukuyama T
Hinyokika Kiyo; 2000 Jul; 46(7):449-52. PubMed ID: 10965448
[TBL] [Abstract][Full Text] [Related]
10. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
Borsellino N; Belldegrun A; Bonavida B
Cancer Res; 1995 Oct; 55(20):4633-9. PubMed ID: 7553641
[TBL] [Abstract][Full Text] [Related]
11. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.
Kitamura T; Nishimatsu H; Hamamoto T; Tomita K; Takeuchi T; Ohta N
Expert Rev Anticancer Ther; 2002 Feb; 2(1):59-71. PubMed ID: 12113067
[TBL] [Abstract][Full Text] [Related]
12. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Meluch AA; Greco FA; Morrissey LH; Raefsky EL; Steis RG; Butts JA; Hainsworth JD;
Cancer; 2003 Nov; 98(10):2192-8. PubMed ID: 14601089
[TBL] [Abstract][Full Text] [Related]
13. [Intermittent oral hormonal chemotherapy using estramustine phosphate and etoposide for the treatment of hormone-refractory prostate cancer].
Kimura M; Sasagawa T; Tomita Y; Katagiri A; Morishita H; Saito T; Tanikawa T; Kawasaki T; Saito K; Nishiyama T; Kasahara T; Hara N; Takahashi K
Hinyokika Kiyo; 2003 Dec; 49(12):709-14. PubMed ID: 14978952
[TBL] [Abstract][Full Text] [Related]
14. Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Schmidt U; Bilkenroth U; Linné C; Fuessel S; Kraemer K; Froehner M; Wirth MP; Meye A
Int J Oncol; 2004 Jun; 24(6):1393-9. PubMed ID: 15138579
[TBL] [Abstract][Full Text] [Related]
15. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
[TBL] [Abstract][Full Text] [Related]
16. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.
Borrega P; Velasco A; Bolaños M; del Mar Perez M; Mel JR; Reina JJ; Rodríguez-Jaraiz MA; Chaves M; González-Barón M
Urol Oncol; 2004; 22(1):32-5. PubMed ID: 14969801
[TBL] [Abstract][Full Text] [Related]
18. The role of chemotherapy in prostate cancer. Minireview.
Odrázka K; Vanásek J; Vaculíková M; Stejskal J; Filip S
Neoplasma; 2000; 47(4):197-203. PubMed ID: 11043822
[TBL] [Abstract][Full Text] [Related]
19. Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines.
Serafin AM; Bohm L
Urol Oncol; 2005; 23(2):123-9. PubMed ID: 15869997
[TBL] [Abstract][Full Text] [Related]
20. [The role of etoposide therapy in urogenital cancer].
Kawai K; Akaza H
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1929-35. PubMed ID: 8978800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
